CONMED (NASDAQ:CNMD) will issue its quarterly earnings data after the market closes on Wednesday, April 25th. Analysts expect the company to announce earnings of $0.44 per share for the quarter. CONMED has set its FY18 guidance at $2.11-2.17 EPS.
CONMED (NASDAQ:CNMD) last posted its quarterly earnings data on Wednesday, January 31st. The medical technology company reported $0.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.04. CONMED had a net margin of 6.97% and a return on equity of 8.96%. The firm had revenue of $222.60 million for the quarter, compared to the consensus estimate of $212.17 million. During the same quarter in the prior year, the company posted $0.54 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, analysts expect CONMED to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
CNMD opened at $62.91 on Monday. CONMED has a 52-week low of $43.88 and a 52-week high of $64.99. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.44 and a current ratio of 2.38. The stock has a market cap of $1,764.12, a PE ratio of 33.29, a P/E/G ratio of 2.55 and a beta of 0.59.
In related news, Director Jo Ann Golden sold 3,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $63.90, for a total value of $191,700.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Terence M. Berge sold 3,868 shares of the stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $62.45, for a total transaction of $241,556.60. Following the completion of the transaction, the vice president now owns 19,908 shares in the company, valued at approximately $1,243,254.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,473 shares of company stock worth $2,874,693. Corporate insiders own 2.62% of the company’s stock.
CNMD has been the topic of several recent analyst reports. BidaskClub downgraded shares of CONMED from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 27th. Zacks Investment Research downgraded shares of CONMED from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. Finally, Needham & Company LLC upped their price objective on shares of CONMED from $58.00 to $71.00 and gave the company a “buy” rating in a report on Thursday, February 1st. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $58.50.
WARNING: “CONMED (CNMD) Set to Announce Quarterly Earnings on Wednesday” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://stocknewstimes.com/2018/04/23/conmed-cnmd-set-to-announce-quarterly-earnings-on-wednesday.html.
CONMED Company Profile
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.